Literature DB >> 19885567

Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through direct interaction.

Akihiko Kidani1, Hiroto Izumi, Yoichiro Yoshida, Eiji Kashiwagi, Haruki Ohmori, Tsuneo Tanaka, Michihiko Kuwano, Kimitoshi Kohno.   

Abstract

Mitochondrial transcription factor A (mtTFA) is a member of the HMG (high mobility group)-box protein family. We previously showed that mtTFA preferentially binds to both cisplatin-damaged and oxidatively damaged DNA. In this study, we found that expression levels of both mtTFA and the mitochondrial antioxidant protein thioredoxin2 (TRX2) are upregulated in cisplatin-resistant cell lines. In addition, TRX2 directly interacts with mtTFA and enhances its damaged DNA binding activity. The interaction between mtTFA and TRX2 requires the HMG box 1 motif of mtTFA. Furthermore, when amino acid substitutions were introduced at either C49G or C246stop, TRX2 interacted with mtTFA. However, the interaction of TRX2 with mtTFA was enhanced when both mutations (C49G and C246stop) were introduced. Binding to cisplatin-damaged DNA was similar among mutant mtTFA proteins. By contrast, binding to oxidized DNA was significantly enhanced when double mutations were introduced. These results suggest that TRX2 not only functions as an antioxidant, but also supports mtTFA functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885567     DOI: 10.3892/ijo_00000462

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway.

Authors:  Yoshihiro Yasuniwa; Hiroto Izumi; Ke-Yong Wang; Shohei Shimajiri; Yasuyuki Sasaguri; Kazuaki Kawai; Hiroshi Kasai; Takashi Shimada; Koichi Miyake; Eiji Kashiwagi; Gen Hirano; Akihiko Kidani; Masaki Akiyama; Bin Han; Ying Wu; Ichiro Ieiri; Shun Higuchi; Kimitoshi Kohno
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

2.  Roles of mitochondrial transcription factor A and microRNA‑590‑3p in the development of colon cancer.

Authors:  Kaiming Wu; Zhenxian Zhao; Yinglian Xiao; Jianjun Peng; Jianhui Chen; Yulong He
Journal:  Mol Med Rep       Date:  2016-11-21       Impact factor: 2.952

3.  Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.

Authors:  Sayo Horibe; Kaori Ishikawa; Kazuto Nakada; Masaki Wake; Norihiko Takeda; Toru Tanaka; Shoji Kawauchi; Naoto Sasaki; Yoshiyuki Rikitake
Journal:  Oncol Rep       Date:  2021-12-22       Impact factor: 3.906

Review 4.  Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy.

Authors:  Kimitoshi Kohno; Ke-Yong Wang; Mayu Takahashi; Tomoko Kurita; Yoichiro Yoshida; Masakazu Hirakawa; Yoshikazu Harada; Akihiro Kuma; Hiroto Izumi; Shinji Matsumoto
Journal:  Int J Mol Sci       Date:  2015-08-20       Impact factor: 5.923

5.  Megakaryocytic differentiation of K562 cells induced by PMA reduced the activity of respiratory chain complex IV.

Authors:  Rui Huang; Long Zhao; Hui Chen; Rong-Hua Yin; Chang-Yan Li; Yi-Qun Zhan; Jian-Hong Zhang; Chang-hui Ge; Miao Yu; Xiao-Ming Yang
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.